Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfa-2b + tenofovir disoproxil fumarate
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
**Peginterferon alfa-2b + tenofovir disoproxil fumarate** is a combination regimen that merges a pegylated recombinant human type I interferon (peginterferon alfa-2b) with a nucleotide reverse transcriptase inhibitor prodrug (tenofovir disoproxil fumarate). Peginterferon alfa-2b acts as an immunomodulator and direct antiviral by binding to type I interferon receptors, activating the JAK/STAT pathway, and upregulating antiviral and antiproliferative responses. Tenofovir disoproxil fumarate, a prodrug of tenofovir, introduces an acyclic nucleotide analog into viral DNA, resulting in premature chain termination and inhibition of viral replication. The combination is under investigation and use for the management of chronic hepatitis B, particularly in patients who are treatment-naïve or previously treated with nucleoside analogs.
- Other names
- peg-IFN-alfa-2b + TDFpegylated interferon alfa-2b + tenofovir disoproxil fumarate
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on peginterferon alfa-2b + tenofovir disoproxil fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfa-2b + tenofovir disoproxil fumarate.